Development Progress
CURRENT LOCATION: HOME > R&D and Innovation > Development Progress

Overview

R&D Centers

Development Progress

Technology Platform

Introduction To Key Projects
Development Progress
R&D Projects Registration Category Indication/Therapeutic Use Phase I Phase II Phase III Approved
PUDK-HGF Biological Products Category 1 Rest pain and/or ischemic ulcers in limbs due to severe ischemic disease of the lower extremities
Remazolam Besylate for Injection New Indication Chemical category 1 Sedation during intensive care unit (ICU)
PARP Inhibitors Chemical category 1 Ovarian cancer, breast cancer, lung cancer, etc
BTK Inhibitors Chemical category 1 Chronic spontaneous urticaria
HW021199 Tablets Chemical category 1 Treatment of idiopathic pulmonary fibrosis
RFUS-144 Injection Chemical category 1 Treatment of pain and pruritus
Bai-re-si Pills Chemical category 1 Treatment of stable vitiligo
Compound Yixie Granules Chemical category 1 Hyperuricemia in the non-acute phase of gout and syndrome of stasis of dampness and turbidness
LL-50 Injection Chemical category 1 Control of surgical anesthesia and acute pain
HW060015 Capsules Chemical category 1 Patients with advanced solid tumors
HW091077 Tablets Chemical category 1 Patients with refractory chronic cough
YJJS-71 Chemical category 1 New skeletal muscle relaxation drug
RF16001 for Injection Chemical category 2 Postoperative analgesia
Sufentanil Transdermal Patch Chemical category 2 Treatment of moderate to severe chronic pain
Oxycodone and Acetaminophen Extended-release Tablets Chemical category 2 Analgesia of moderate to severe neuralgia
Tapentadol Hydrochloride Preparations Chemical category 3 Relief of moderate to severe pain in adults of 18 years of age and older; treatment of pain that requires long-term treatment with opioid analgesics
Fentanyl Citrate Oral Patch Chemical category 3 For the treatment of explosive pain in patients with cancerous pain who have been using opioids continuously
Methylnaltrexone Bromide Preparations Chemical category 3 For the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancerous pain

CURRENT LOCATION:

HOME > R&D and Innovation> Development Progress
About Us
Group Introduction
Management Team
Development Strategy
Corporate Culture
Milestones
News
News
Global
Global Layout
Asia
North America
Africa
Europe
Products
API
Preparation
R&D and Innovation
Overview
R&D Centers
Development Progress
Technology Platform
Introduction To Key Projects
Partnership
We Seek
We Offer
Investor Relations
Corporate Governance
Financial Highlight
Periodical
Ad-hoc
Investor Interaction

COPYRIGHT 2024 HUMANWELL GROUP ALL RIGHTS RESERVED.

Privacy protection Legal statement
Technical Support: Lucky xp
Group Subsidiary GROUP SUBSIDIARY
Yichang Humanwell Pharmaceutical Co., Ltd Hubei Gedian Humanwell Pharmaceutical Co.,Ltd. Wuhan Humanwell Pharmaceutical Co., Ltd Xinjiang Uyghur Pharmaceutical Co., Ltd. Humanwell Puke Pharmaceutical (Wuhan) Co., Ltd Yichang Sanxia Pharmaceutical Co., Ltd Epic Pharma, LLC Beijing Baron Medical Equipment Co., Ltd. Wuhan Tianrun Health Products Co., Ltd.
QRCode
Group Subsidiary GROUP SUBSIDIARY
Yichang Humanwell Pharmaceutical Co., Ltd Hubei Gedian Humanwell Pharmaceutical Co.,Ltd. Wuhan Humanwell Pharmaceutical Co., Ltd Xinjiang Uyghur Pharmaceutical Co., Ltd. Humanwell Puke Pharmaceutical (Wuhan) Co., Ltd Yichang Sanxia Pharmaceutical Co., Ltd Epic Pharma, LLC Beijing Baron Medical Equipment Co., Ltd. Wuhan Tianrun Health Products Co., Ltd.
QRCode

COPYRIGHT 2024 HUMANWELL GROUP ALL RIGHTS RESERVED.

Privacy protection Legal statement
Technical Support: Lucky xp
0.288869s